Investors Relations
COMPANY PROFILE
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
INDUSTRY CLASSIFICATIONS
Sector: Health Care
Industry: Industrial Specialties
About us
The Core focus for Nutriband is to do our part to fight the Opioid epidemic currently sweeping the nation and internationally. Fentanyl and other opioid based transdermal medications unfortunately play a role in a significant number of opioid deaths each year. Working with our Clinical subsidiary 4P Therapeutics we have developed a patent pending technology called AVERSA which we believe with FDA approval will revolutionize the safety standard for these medications and save countless lives per year.
To view our latest presentation, please click here.
